Severe adverse reactions prompt call for trial design changes.
Susan
S
Mayor
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology; D061067:Antibodies, Monoclonal, Humanized; D018106:CD28 Antigens / Q000009:adverse effects / Q000276:immunology; D017321:Clinical Trials, Phase I as Topic / Q000592:standards*; D006805:Human Experimentation / Q000592:standards*; D006801:Humans; D008297:Male; D009102:Multiple Organ Failure / Q000209:etiology; D011948:Receptors, Antigen, T-Cell / Q000819:agonists; D012107:Research Design / Q000592:standards*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018106:CD28 Antigens; D011948:Receptors, Antigen, T-Cell; C509303:TGN-1412